Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H16ClNO4 |
Molecular Weight | 357.788 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C(CC(O)=O)C2=C1
InChI
InChIKey=CGIGDMFJXJATDK-UHFFFAOYSA-N
InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
DescriptionCurator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02183168 | https://clinicaltrials.gov/ct2/show/NCT02770950 | https://www.ncbi.nlm.nih.gov/pubmed/20503989 | https://www.ncbi.nlm.nih.gov/pubmed/14056924 | https://www.ncbi.nlm.nih.gov/pubmed/27988363
Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02183168 | https://clinicaltrials.gov/ct2/show/NCT02770950 | https://www.ncbi.nlm.nih.gov/pubmed/20503989 | https://www.ncbi.nlm.nih.gov/pubmed/14056924 | https://www.ncbi.nlm.nih.gov/pubmed/27988363
Indometacin (INN and BAN) or indomethacin (AAN, USAN, and former BAN) is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. Indomethacin has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of Indometacin, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Indomethacin is a potent inhibitor of prostaglandin synthesis in vitro. Indomethacin concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because indomethacin is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues. Indometacin is indicated for: Moderate to severe rheumatoid arthritis including acute flares of chronic disease, Moderate to severe ankylosing spondylitis, Moderate to severe osteoarthritis, Acute painful shoulder (bursitis and/or tendinitis), Acute gouty arthritis. In general, adverse effects seen with indomethacin are similar to all other NSAIDs. For instance, indometacin inhibits both cyclooxygenase-1 and cyclooxygenase-2, it inhibits the production of prostaglandins in the stomach and intestines, which maintain the mucous lining of the gastrointestinal tract. Indometacin, therefore, like other non-selective COX inhibitors can cause peptic ulcers. These ulcers can result in serious bleeding and/or perforation requiring hospitalization of the patient. To reduce the possibility of peptic ulcers, indomethacin should be prescribed at the lowest dosage needed to achieve a therapeutic effect, usually between 50–200 mg/day. It should always be taken with food. Nearly all patients benefit from an ulcer protective drug (e.g. highly dosed antacids, ranitidine 150 mg at bedtime, or omeprazole 20 mg at bedtime). Other common gastrointestinal complaints, including dyspepsia, heartburn and mild diarrhea are less serious and rarely require discontinuation of indomethacin.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11906281 |
3.0 nM [IC50] | ||
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20503989 |
10.0 nM [IC50] | ||
Target ID: CHEMBL4681 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23432095 |
100.0 nM [IC50] | ||
Target ID: CHEMBL1835 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2547071 |
100.0 nM [IC50] | ||
Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12142058 |
|||
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12142058 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date1965 |
|||
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date1965 |
|||
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date1965 |
|||
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date1965 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2369 ng/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2 μg/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7762 ng × h/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.22 h |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Disc. AE: Vomiting, Nausea... AEs leading to discontinuation/dose reduction: Vomiting Sources: Page: p.152Nausea (mild) Anorexia (mild) |
20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Other AEs: Headache, Pruritus... Other AEs: Headache (below serious, 11 patient) Sources: Pruritus (below serious, 5 patients) |
20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (below serious, 34 patients) Sources: Vomiting (below serious, 11 patient) Constipation (below serious, 8 patients) |
40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Other AEs: Deep vein thrombosis, Headache... Other AEs: Deep vein thrombosis (serious, 1 patient) Sources: Headache (below serious, 13 patients) Pruritus (below serious, 1 patient) Presyncope (below serious, 5 patients) |
40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (below serious, 36 patients) Sources: Vomiting (below serious, 12 patients) Constipation (below serious, 7 patients) Post procedural haemorrhage (below serious, 7 patients) |
40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Other AEs: Headache, Pruritus... Other AEs: Headache (below serious, 12 patients) Sources: Pruritus (below serious, 3 patients) |
40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 94 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 94 Sources: |
Other AEs: Headache, Vomiting... Other AEs: Headache (below serious, 17 patients) Sources: Vomiting (below serious, 9 patients) |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Disc. AE: Cardiac thrombosis, Myocardial infarction... AEs leading to discontinuation/dose reduction: Cardiac thrombosis (serious) Sources: Myocardial infarction (grade 3-5) Stroke (grade 3-5) Gastrointestinal disorder NOS (serious) Bleeding (grade 3-5) Ulceration (grade 3-5) Perforation stomach (grade 3-5) Perforation of intestine (grade 3-5) |
0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Other AEs: Gingival bleeding, Application site pruritus... Other AEs: Gingival bleeding (below serious, 1 patient) Sources: Application site pruritus (below serious, 1 patient) Inflammation (below serious, 1 patient) Nasopharyngitis (below serious, 1 patient) Ligament sprain (below serious, 1 patient) Rash (below serious, 2 patients) Drug eruption (below serious, 1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vomiting | Disc. AE | 0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Anorexia | mild Disc. AE |
0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Nausea | mild Disc. AE |
0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Headache | below serious, 11 patient | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Pruritus | below serious, 5 patients | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Vomiting | below serious, 11 patient | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Nausea | below serious, 34 patients | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Constipation | below serious, 8 patients | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Pruritus | below serious, 1 patient | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Headache | below serious, 13 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Presyncope | below serious, 5 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Deep vein thrombosis | serious, 1 patient | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Vomiting | below serious, 12 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Nausea | below serious, 36 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Constipation | below serious, 7 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Post procedural haemorrhage | below serious, 7 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Headache | below serious, 12 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Pruritus | below serious, 3 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Headache | below serious, 17 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 94 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 94 Sources: |
Vomiting | below serious, 9 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 94 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 94 Sources: |
Bleeding | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Myocardial infarction | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Perforation of intestine | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Perforation stomach | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Stroke | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Ulceration | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Cardiac thrombosis | serious Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Gastrointestinal disorder NOS | serious Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Application site pruritus | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Drug eruption | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Gingival bleeding | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Inflammation | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Ligament sprain | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Nasopharyngitis | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Rash | below serious, 2 patients | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Evaluation of the effects of some non-steroid anti-inflammatory agents on the gastric mucosa]. | 1976 Jul 7 |
|
Endogenous prostaglandin formation in the field-stimulated guinea-pig vas deferens: comparison of the inhibitory effects of indomethacin and NS-398. | 1999 Dec |
|
Decrease in nucleophosmin/B23 mRNA and telomerase activity during indomethacin-induced apoptosis of gastric KATO-III cancer cells. | 1999 Dec |
|
Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. | 1999 Dec |
|
Prostaglandin-independent anovulatory mechanism of indomethacin action: inhibition of tumor necrosis factor alpha-induced sheep ovarian cell apoptosis. | 1999 Dec |
|
The influence of indomethacin on the metabolism and cytokine secretion of human aneurysmal aorta. | 1999 Jul |
|
Prostaglandins and leukotriene B4 are potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 2 activity in human choriocarcinoma JEG-3 cells. | 1999 Jul |
|
Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. | 1999 Jul 6 |
|
Induction of stromelysin gene expression by tumor necrosis factor alpha is inhibited by dexamethasone, salicylate, and N-acetylcysteine in synovial fibroblasts. | 1999 Jun |
|
Indomethacin treatment slows disease progression and enhances a Th1 response in susceptible BALB/c mice infected with Leishmania major. | 1999 May |
|
Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. | 1999 May |
|
Enhancement of low density lipoprotein catabolism by non-steroidal anti-inflammatory drugs in cultured HepG2 cells. | 1999 May 21 |
|
Indomethacin reduces the skin thermal damage in hyperthermic treatment of experimental malignant tumors. | 1999 May-Jun |
|
Capsaicin-sensitive afferent sensory nerves in modulating gastric mucosal defense against noxious agents. | 1999 Nov |
|
Effect of anti-CD11b (alphaM-MAC-1) and anti-CD54 (ICAM-1) monoclonal antibodies on indomethacin induced chronic ileitis in rats. | 1999 Nov |
|
Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. | 1999 Nov |
|
Indomethacin treatment decreases renal blood flow velocity in human neonates. | 1999 Nov |
|
Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion-induced gastric lesions. | 1999 Nov 26 |
|
Reactive oxygen species are involved in the apoptosis induced by nonsteroidal anti-inflammatory drugs in cultured gastric cells. | 1999 Nov 3 |
|
Can dopamine prevent the renal side effects of indomethacin? A prospective randomized clinical study. | 1999 Nov-Dec |
|
Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. | 1999 Oct 2 |
|
Dual action of nitric oxide in pathogenesis of indomethacin-induced small intestinal ulceration in rats. | 1999 Sep |
|
Sulindac inhibits activation of the NF-kappaB pathway. | 1999 Sep 17 |
|
[Effect of carrageenan and indomethacin on the growth of a murine fibrosarcoma]. | 2000 |
|
Chronic intrathecal cannulation enhances nociceptive responses in rats. | 2000 Aug |
|
Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model. | 2000 Dec |
|
Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen. | 2000 Dec 8 |
|
Bartter syndrome in a neonate: early treatment with indomethacin. | 2000 Feb |
|
Characterization of M cell development during indomethacin-induced ileitis in rats. | 2000 Feb |
|
Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. | 2000 Feb 11 |
|
Enhanced protein denaturation in indomethacin-treated cells. | 2000 Jan |
|
Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. | 2000 Jan |
|
Inhibition of carrageenan-induced edema by indomethacin or sodium salicylate does not prevent the increase of nerve growth factor in the rat hind paw. | 2000 Jan 14 |
|
Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression. | 2000 Jul-Aug |
|
Effect of indomethacin on IL-1beta, IL-6 and TNFalpha production by mononuclear cells of preterm newborns and adults. | 2000 Mar |
|
In vivo indomethacin treatment causes microglial activation in adult mice. | 2000 Mar |
|
Prevention and healing of experimental indomethacin-induced gastric lesions: effects of ebrotidine, omeprazole and ranitidine. | 2000 Mar |
|
Overexpression of protein kinase C-beta1 isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial cells. | 2000 Mar |
|
Effects of hydrogen peroxide scavenger Catalase on villous microcirculation in the rat small intestine in a model of inflammatory bowel disease. | 2000 May |
|
Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. | 2000 Nov |
|
Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin. | 2000 Nov |
|
Inhibition of inducible nitric oxide synthase gene expression by indomethacin or ibuprofen in beta-amyloid protein-stimulated J774 cells. | 2000 Nov 17 |
|
Indomethacin inhibits the accumulation of tumor cells in mouse lungs and subsequent growth of lung metastases. | 2000 Nov-Dec |
|
Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways. | 2000 Sep 8 |
|
Effect of the nonsteroidal anti-inflammatory drug indomethacin on proliferation and apoptosis of colon carcinoma cells. | 2001 |
|
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. | 2001 Jan |
|
Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells. | 2001 Mar |
|
Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. | 2001 Mar |
|
Indomethacin prevents the induction of inducible nitric oxide synthase in murine peritoneal macrophages and decreases their nitric oxide production. | 2001 Mar 9 |
|
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice. | 2001 Mar 9 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27988363
U251 cells were incubated for 24 h with different concentrations of indomethacin (0.03, 0.06, 0.13, 0.25, 0.5, 1 mkM), diclofenac (DIC),naproxen (NAP), or ketoprofen (KET), and the cell viability was assessed by MTT or crystal violet (CV) tests.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000000160
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
||
|
NCI_THESAURUS |
C1323
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
||
|
WHO-VATC |
QS01BC01
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
||
|
WHO-VATC |
QC01EB03
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
||
|
NCI_THESAURUS |
C54677
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
||
|
NDF-RT |
N0000175721
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
||
|
LIVERTOX |
NBK548001
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
||
|
WHO-ATC |
M02AA23
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
||
|
NDF-RT |
N0000175722
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
||
|
WHO-VATC |
QM01AB01
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
||
|
WHO-ATC |
M01AB01
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
||
|
WHO-ATC |
S01BC01
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
||
|
WHO-VATC |
QM02AA23
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
||
|
WHO-ATC |
S01CC02
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
||
|
WHO-VATC |
QM01AB51
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
||
|
WHO-ATC |
M01AB51
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
||
|
WHO-ATC |
C01EB03
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL6
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
DB00328
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
m6279
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | Merck Index | ||
|
5781
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | RxNorm | ||
|
D007213
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
Indomethacin
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
XXE1CET956
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
DTXSID9020740
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
SUB08180MIG
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
100000092758
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
49662
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
757061
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
XXE1CET956
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
1524
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
77541
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
1341001
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
3101
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
3715
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
INDOMETHACIN
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | Description: A white or a pale yellow, crystalline powder; odourless or almost odourless. Solubility: Practically insoluble in water; sparingly soluble in ethanol (~750 g/l) TS and ether R. Category: Analgesic; anti-inflammatory. Storage: Indometacin should be kept in a well-closed container, protected from light. Additional information: Indometacin exhibits polymorphism. The polymorph specified in the monograph corresponds to the crystal form of indometacin RS.Definition: Indometacin contains not less than 98.0% and not more than 101.0% of C19H16ClNO4, calculated with reference to the dried substance. | ||
|
1440
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
C576
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
53-86-1
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
1909
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
200-186-5
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY | |||
|
INDOMETACIN
Created by
admin on Fri Dec 15 15:07:35 GMT 2023 , Edited by admin on Fri Dec 15 15:07:35 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
PRODRUG (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)